1Med
7
3
3
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 7 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
Evaluation of Performance and Safety of INNEA and INNEA AQUA for the Treatment of Cheek and décolletage Wrinkles
Role: collaborator
Clinical Investigation on a Polynucleotide-based Device Used to Improve Skin Hydration
Role: collaborator
REACH: RWE Retrospective Study to Evaluate Cenobamate Impact on Health Care Resource Utilization
Role: collaborator
Efficacy and Safety of PN+HA (NEWEST) for the Improvement of Skin Hydration
Role: collaborator
POST-MARKETING CLINICAL STUDY to EVALUATE the EFFICACY and SAFETY of the VAGINAL FILLER MEDICAL DEVICE in CORRECTING THINNING of the GENITAL TISSUE of the LABIA MAJORA in WOMEN, RE-PROPORTIONING the FEMALE EXTERNAL GENITAL AREA and IMPROVING SEXUAL FUNCTION.
Role: collaborator
An Interventional Study to Evaluate the Safety and Performance of Crosslinked Hyaluronic Acid Hydrogel
Role: collaborator
L. Casei DG® in Patients With Irritable Bowel Syndrome.
Role: collaborator
All 7 trials loaded